A study to characterise the safety, tolerability and efficacy of LY3962673 in subjects with advanced solid tumors.
J5J-OX-JZZA
Phase 1 other active
Quick answer
A study to characterise the safety, tolerability and efficacy of LY3962673 in subjects with advanced solid tumors. for KRAS G12D-mutant solid tumors. is a Phase 1 program (other) at Eli Lilly Co. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eli Lilly Co.
- Indication
- KRAS G12D-mutant solid tumors.
- Phase
- Phase 1
- Modality
- other
- Status
- active